Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

3.610 +1.140 (+46.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Looking Into Cabaletta Bio's Recent Short Interest
 
Via Benzinga
Peering Into Cabaletta Bio's Recent Short Interest
 
Via Benzinga
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
From Cabaletta Bio
Via GlobeNewswire
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode
U.S. stock futures advanced on Friday after a day's break for Thanksgiving as investors look to end November on a high note. 
Via Benzinga
Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial
 
Via Benzinga
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q2 2024
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
From Cabaletta Bio
Via GlobeNewswire
Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.